07.02.2019 Elanix Biotechnologies AG  DE000A0WMJQ4

DGAP-Adhoc: Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board


 

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Personnel/AGM/EGM
Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board

07-Feb-2019 / 14:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board

Berlin, February 7, 2019 - The new major shareholder of Elanix Biotechnologies AG ("Company", "Elanix"), Mrs. Fang Bao, has announced that she requests to convene an extraordinary shareholder meeting to replace the chairman of the supervisory board, Mr. Jürgen Kullmann.

His deputy, Mrs. Abigael de Buys Roessingh, announced today to resign from the Supervisory Board with effect from 8 March 2019. A successor should be appointed by juridical order in a timely manner.

Mrs. Fang Bao will remain in office as Supervisory Board member. A date and the agenda for the General Meeting have not yet been announced. The Management Board will keep the shareholders informed.

Lee-Ann Laurent-Applegate
CEO

Contacts

Elanix Biotechnologies AG
Lee-Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
investor.relations@elanix-bt.com

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


07-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
Stadthausbrücke 1-3
20355 Hamburg
Germany
Phone: +41 22 363 66 40
Fax: +41 22 363 66 41
E-mail: info@elanix-bt.com
Internet: www.elanixbiotechnologies.com
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

 
End of Announcement DGAP News Service

773665  07-Feb-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=773665&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,33 0,06 0,00
EBITDA1,2 0,00 0,00 0,00 -3,16 -2,32 -3,13 -3,65 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 -948,48 -6.083,33 0,00
EBIT1,4 0,00 0,00 0,00 -3,16 -2,32 -4,39 -3,67 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 -1.330,30 -6.116,67 0,00
Jahresüberschuss1 0,00 0,00 0,00 -2,79 -1,89 -3,83 -3,73 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 -1.160,61 -6.216,67 0,00
Cashflow1,7 0,00 0,00 0,00 -0,54 -0,82 -3,77 -2,55 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 -0.54 -0,36 -0,58 -0,49 -0,17
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Elanix Biotechnologies
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0WMJQ 0,598 4,83
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 6,40 0,000 0,00
KBV KCV KUV EV/EBITDA
-2,40 - 79,22 -1,393
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 24.08.2017
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2019 19.08.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-32,29% -57,25% -56,35% -76,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Elanix Biotechnologies AG  ISIN: DE000A0WMJQ4 können Sie bei DGAP abrufen

Biotechnologie , A0WMJQ , ELN , FWB:ELN